Download PDF
Zeitschrift für Orthomolekulare Medizin 2018; 16(03): 15-21
DOI: 10.1055/s-0038-1675438
Wissen
© Georg Thieme Verlag KG Stuttgart · New York

Schadstoffe als Ursache oder Auslöser endokriner Störungen und chronischer Erkrankungen

Aminosäuren in Prävention und Therapie
Claus Schulte-Uebbing
,
Martin Landenberger
,
Florian Pfab
,
Liana Antal
Further Information

Publication History

Publication Date:
11 October 2018 (online)

    Permissions and Reprints

Zusammenfassung

Pestizide, Schwermetalle, Weichmacher, Schadstoffe aus dem Tabakrauch und andere Substanzen wirken als Endokrine Disruptoren und können chronische Erkankungen und Tumorwachstum fördern sowie Alterungsprozesse von Geweben beschleunigen. Aminosäuren sind in der Lage, neoplastischen Prozessen entgegenzuwirken, beeinflussen neurochemische Resilienzfaktoren und ZNS-Faktoren positiv, beugen Insulinresistenz und damit Diabetes vor. Auch für die Detoxifikation eliminationspflichtiger lipophiler Substrate ist die ausreichende Versorgung mit Aminosäuren notwendig. Endokrine Disruptoren können immunologische und neurologische Regelkreise stören, den Aminosäurestoffwechsel empfindlich beeinträchtigen und zu einem deutlich erhöhten Bedarf an Aminosäuren führen. Eine gezielte individuelle laborkontrollierte Aminosäurezufuhr kann ein effektives therapeutisches Element in der angewandten Präventivmedizin sein.

Schlüsselwörter

Schadstoffe - Endokrine Disruptoren - Aminosäuren - estrogene Aktivität - Schwermetalle - Pestizide - Phthalate - Karzinome - endogene Regelkreise - Depression - Demenz - Insulinresistenz - Adrenal Insufficiency Syndrome - DHEA - Gehirnfunktion - gonadale Dysfunktion - Detoxifikation - Glukosestoffwechsel - Alterungsprozesse
 

  • Literatur

  • 1 Jennrich P. Schwermetalle und Krebs, Auswirkungen bisher wenig beachtet. Co Med 2008; 7: 1-5
  • 2 Liu et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric Food Chem 2001; 49: 2472-2479
    CrossrefPubMedGoogle Scholar
  • 3 Laden F, Ishibe N. et al. Polychlorinated biphenyls and breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11 (12) : 1560-1565
    PubMedGoogle Scholar
  • 4 Saintot M. , Malaveille et al. Interaction between genetic polymorphism of cytochrome P450 and environmental pollutants in breast cancer risk. Eur J Cancer Prev 2004; 13 (01) : 83-86
    CrossrefPubMed
  • 5 Seidel HJ. Klinische Umweltmedizin; Achen: Shaker; 2005
    PubMed
  • 6 Darbre PD. Environmental oestrogens, cosmetics and breast cancer; Clin Endocrinol Metabol 2006; 20 (01) : 121-143
    PubMed
  • 7 Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 2003; 111 (04) : 389-394
    CrossrefPubMed
  • 8 Schulte-Uebbing C. Schwermetall-Metabolismus bei Endokrinologischen Krankheiten. Workshop, Ärztegesellschaft für Klinische Metalltoxikologie. Frankfurt, 2009-3-09
  • 9 Davis DL, Bradlow HL, Wolff M. et al. Xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 1993; 101 (05) : 372-377
    CrossrefPubMedGoogle Scholar
  • 10 López-Carrillo L, Hernández-Ramírez RU, Calafat AM. et al. Exposure to Phthalates and Breast Cancer Risk in Northern Mexico. Environ Health Perspect 2010; 118: 539-544
    CrossrefPubMedGoogle Scholar
  • 11 Shlomo, Melmed, Kenneth et al., Hrsg. Williams Textbook of Endocrinology, 13th ed.. Elsevier; 2015
  • 12 Hibbeler B. Demenz: Weltweit fast zehn Millionen Neuerkrankungen, Dtsch Arztebl 2015; 112 (37) : A-1470
  • 13 Monsell SE, Kukull WA, Roher AE. et al. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques;. JAMA Neurol 2015; 72: 1124-1131
    CrossrefPubMedGoogle Scholar
  • 14 Willix RD, Barber MJ. Update on Alzheimer’s Disease; Medscape 2007
    PubMed
  • 15 Krishna Mohan I, Das UN. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radical Biology and Medicine 1998; 25 (07) : 757-765
    CrossrefPubMed
  • 16 Piatti PM, Monti LD, Valsecchi G. et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients; Diabetes Care 2001; 24 (05) : 875-880
    PubMed
  • 17 Hoang HH, Padgham SV, Meininger CJ. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes. Current Opinion in Clinical Nutrition & Metabolic Care 2013; 16 (01) : 76-82
    CrossrefPubMed
  • 18 Rajapakse NW, Chong AL, Zhang WZ, Kaye DM. Insulin-Mediated Activation of the L-Arginine Nitric Oxide Pathway in Man, and Its Impairment in Diabetes; PloS one 2013; 8 (05) : e61840
    PubMed
  • 19 Arana V, Paz Y, González A. et al. Healing of diabetic foot ulcers in L-arginine-treated patients, Biomed Pharmacother 2004; 58: 588-597
    PubMed
  • 20 Power RA, Hulver MW, Zhang JY. et al. Carnitine revisted: potential use as adjunctive treatment; Diabetes Diabetologia 2007; 50 (04) : 824-832
  • 21 Teusink B, Diderich JA, Westerhoff HV. Intracellular Glucose Concentration in Derepressed Yeast Cells Consuming Glucose Is High Enough To Reduce the Glucose Transport Rate by 50 %. J Bacteriol 1998; 180 (03) : 556-562
    PubMed
  • 22 Shugart C, Jackson J, Fields KB. Diabetes in Sports. Sports Health 2010; 2 (01) : 29-38
    CrossrefPubMed
  • 23 Wang TJ. et al. Metabolite profiles and the risk of developing diabetes; Nature Medicine 2011; 17: 448
    PubMed
  • 24 Fischer E. et al. Therapy of depression by phenylalanine. Arzneimittelforsch 1985; 25: 132
    Google Scholar
  • 25 Morris R. DL-Phenylalanine: Relief from the Chronic Pain of Exercise. Natural Physique 1992; 6: 735-738
  • 26 Colin MD, Panicker V. Hypothyroidism and Depression; Eur Thyroid J 2013; 2 (03) : 168-179
    PubMed
  • 27 Schulte-Uebbing C. Depressive Verstimmungen, Müdigkeit, Leistungsschwäche – Morbus Hashimoto: Häufig übersehene wichtige (Teil-) Ursache; gyn 2014 19. 48-54
    PubMed
  • 28 Almeida OP, Barclay L. Sex hormones and their impact on dementia and depression: a clinical perspective; Expert Opin Pharmacother 2001; 2 (04) : 527-535
    PubMed
  • 29 Glick ID, Bennett SE. Psychiatric complications of progesterone and oral contraceptives; J Clin Psychopharmacol 1981; 1 (06) : 350-367
    PubMed
  • 30 Nadjafi-Triebsch C, Huell M, Burki D, Rohr DU. Progesterone increase under DHEA-substitution in males. Maturitas 2003; 45 (03) : 231-235
    CrossrefPubMed
  • 31 Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: A continuum of vulnerability? J Psychiatry Neurosci 2008; 33 (04) : 331-343
    PubMed
  • 32 Mukherjee S, Newby E, Harvey JN. Adrenomyeloneuropathy in patients with ‘Addison’s disease’: genetic case analysis. J R Soc Med 2006; 99 (05) : 245-249
    PubMed
  • 33 Wedlock N, Asawa T, Baumann A. et al. Autoimmune Addison’s disease: Analysis of autoantibody binding sites on human steroid 21-hydroxylase; FEBS Letters 1993; 332 (1–2 ): 123-126
    PubMed
  • 34 Kimonides VG, Khatibi NH, Svendsen CM. et al. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity; Proc Natl Acad Sci U S A 1998; 95 (04) : 1852-1857
    PubMed
  • 35 Peixoto C, Devicari Cheda JN, Nardi AE. et al. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review. Drug Targets 2014; 15 (09) : 901-914
    Google Scholar
  • 36 Fabian TJ, Dew MA, Pollock BG. et al. Endogenous Concentrations of DHEA and DHEA-S Decrease with Remission of Depression in Older Adults. Biol Psychiatry 2001; 50: 767-777
    CrossrefPubMedGoogle Scholar
  • 37 Aly HF, Metwally FM, Ahmed HH. Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease. Acta Biochim Pol, 2011; 58 (04) : 513-520
    PubMed
  • 38 Mikeladze M, Hedrington MS, Joy N. et al. Acute Effects of Oral Dehydroepiandrosterone on Counterregulatory Responses During Repeated Hypoglycemia in Healthy Humans; Diabetes 2016; 65 (10) : 3161-3170
    PubMed
  • 39 Wolkowitz OM, Reus VI, Keebler A. et al. Double-Blind Treatment of Major Depression With Dehydroepiandrosterone; Am J Psychiatry 1999; 156: 4
  • 40 Brahimaj A, Muka T, Kavousi M. et al. Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam Study. Diabetologia 2017; 60 (01) : 98-106 .
    CrossrefPubMedGoogle Scholar
  • 41 De Heredia FP, Cerezo D, Zamora S, Garaulet M. Effect of dehydroepiandrosterone on protein and fat digestibility, body protein and muscular composition in high-fat-diet-fed old rats; Br J Nutr 2007; 97 (03) : 464-470
    PubMed
  • 42 Auro K, Joensuu A, Fischer K. et al. A metabolic view on menopause and ageing; Nature Communications 2014 5. 4708
    PubMed
  • 43 Gould DC, Petty R. The male menopause: does it exist? West J Med 2000; 173 (02) : 76-78
    PubMed
  • 44 Maki PM, Dumas J. Mechanisms of Action of Estrogen in the Brain: Insights from Human Neuroimaging and Psychopharmacologic Studies. Semin Reprod Med 2009; 27 (03) : 250-259
    Article in Thieme ConnectPubMed
  • 45 Harburger LL, Bennett JC, Frick KM. Effects of estrogen and progesterone on spatial memory consolidation in aged females. Neurobiol Aging 2007; 28 (04) : 602-610
    CrossrefPubMed
  • 46 Toran-Allerand CD, Singh M, Sétáló G Jr. Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinol 1999; 20 (02) : 97-121
    CrossrefPubMed
  • 47 Imtiaz B, Tuppurainen M, Rikkonen T. et al. Postmenopausal hormone therapy and Alzheimer disease, A prospective cohort study. Neurology 2017; 88 (11) : 1062-1068
    CrossrefPubMedGoogle Scholar
  • 48 Rybaczyk LA, Bashaw MJ, Pathak DR. et al. An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health 2005; 20 (05) : 12
    Google Scholar
  • 49 Benmansour S, Adeniji OS, Privratsky AA, Frazer A. Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats. Neuroendocrinology 2016; 103: 269-281
    CrossrefPubMedGoogle Scholar
  • 50 Van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? Semin Clin Neuropsychiatry 2000; 5 (02) : 125-131
    PubMed
  • 51 Hong SY, Yang DH, Chang SK. The relationship between plasma homocysteine and amino acid concentrations in patients with end-stage renal disease. J Ren Nutr 1998; 8 (01) : 34-39
    CrossrefPubMedGoogle Scholar
  • 52 Seshadri MD. et al. Plasma Homocysteine as a Risk Factor for Dementia and Azheimer’s Disease. N Engl Med J 2002; 346 (07) : 476-483
    CrossrefPubMedGoogle Scholar
  • 53 Hodges RE, Minich DM. Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application. J Nutr Metab 2015; 2015: 760689
    PubMedGoogle Scholar
  • 54 Grant DM. : Detoxification pathways in the liver. J Inherit Metab Dis., 1991; 14 (04) : 421-430
    PubMed
  • 55 Mauvais-Jarvis F, Clegg DJ, Hevener AL. The Role of Estrogens in Control of Energy Balance and Glucose. Endocr Rev 2013; 34 (03) : 309-338
    CrossrefPubMed
  • 56 Piatti PM, Monti LD, Valsecchi G. et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001; 24 (05) : 875-880
    CrossrefPubMedGoogle Scholar
  • 57 Hoang HH, Padgham SV, Meininger CJ. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes. Current Opinion in Clinical Nutrition & Metabolic Care 2013; 16 (01) : 76-82
    CrossrefPubMed
  • 58 Malaguarnera M, Vacante M, Avitabile T. et al. L-carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. American Journal of Clinical Nutrition 2009; 89 (01) : 71-76
    CrossrefPubMedGoogle Scholar
  • 59 Howdeshell KL. et al. Mechanisms of action of phthalate esters, individually and in combination. Environmental Research 2008; 108 (02) : 168-176
    CrossrefPubMedGoogle Scholar
  • 60 WECF. Endokrine Disruptoren und das weibliche Fortpflanzungssystem. Bericht über den Workshop „The Womens’s Reproductive Health and the Environment” 2014
    PubMed
  • 61 Gerhard I. Das Frauen-Gesundheitsbuch: Wo Naturheilverfahren wirken, wann Schulmedizin nötig ist. Stuttgart: Trias; 2014
  • 62 Schulte-Uebbing C, Schlett S, Craiut ID. Werden hormonabhängige Tumoren (Eierstock, Gebärmutter, Brust) durch Morbus Hashimoto gefördert?, CO MED 2014: 40-42
    PubMed
  • 63 Blount BC. et al. Levels of Seven Urinary Phthalate Metabolites in a Human Reference Population. Environmental Health Perspectives 2000; 108 (10) : 979-982
    PubMedGoogle Scholar
  • 64 Duty SM, Singh NP, Silva MJ. et al. The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay. Environmental Health Perspectives 2003; 111 (09) : 1164-1169
    CrossrefPubMedGoogle Scholar
  • 65 Fang-Ping C, Mei-Hua C, Ying-Yu-Chen I. Impact of low concentrations of phthalates on the effects of 17β-estradiol in MCF-7 breast cancer cells. Taiwanese Journal of Obstetrics and Gynecology 2016; 55 (06) : 826-834
    CrossrefPubMed
  • 66 Tallberg T. Development of a Combined Biological and Immunological Cancer Therapy Modality. J Aust Coll Nutr & Env Med 2003; 22 (01) : 3-21